Abstract: Hepatocellular carcinoma (HCC) has a high incidence in China. Most of HCC patients are in the intermediate or advanced stages when diagnosed, with poor response to conventional therapies. Seeking new effective treatments and adopting reasonable multidisciplinary and comprehensive treatment strategies are key points to improve the prognosis of these patients. In recent years, domestic scholars have innovatively applied the oxaliplatin-based FOLFOX regimen to hepatic artery infusion chemotherapy (HAIC), which has significantly improved the tumor response rate and patient survival rate, and has received more and more attention and been more widely used. The Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition) is a collection of the experiences from Chinese experts in the field of HAIC for HCC, aiming to use it as a prototype to seek common ground while reserving differences, and to apply HAIC in the treatment of HCC in a more rational and effective way.